White & Case Advises Takeda on Agreement to Divest Select OTC and Non-core Assets in Latin America to Hypera Pharma for US$825 Million
1 min read
Global law firm White & Case LLP has advised Takeda Pharmaceutical Company Limited (Takeda) on an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical products in Latin America countries within its Growth and Emerging Markets Business Unit to Hypera Pharma for a total value of US$825 million.
Takeda is a global biopharmaceutical leader headquartered in Japan, primarily focused on five business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience.
Hypera Pharma is Brazil's largest pharmaceutical company with a leading position in branded prescriptions, consumer health and branded generics.
The White & Case team which advised on the transaction was led by partners Michael Immordino and Leonardo Graffi (both Milan and London) and included partners Philip Trillmich, Monica Holden, Dominic Ross, Martin Forbes and Gilles Teerlinck (all London), Arlene Hahn and David Dreier (both New York) and Axel Schulz (Brussels), counsel Isaac Tendler (New York) and associates Andrea Pretti, Fabrizia Faggiano and Alessandro Piga (all Milan), Ajita Shukla (Washington, DC), Kyle Oh (Seoul and Singapore), Mariana Seixas (San Paulo), Benjamin Snow (New York), Tommaso Poli (Brussels) and lawyer Mariasole Maschio (Milan).
White & Case has also advised Takeda on other agreements of divestiture of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical products in Near East, Middle East and Africa (NEMEA) countries, Russia, Georgia, and a number of countries from within the Commonwealth of Independent States in 2019.
For more information please speak to your local media contact.